Burning Rock Biotech Limited (BNR) Fair Value & Analysis
Healthcare · US · Market cap $74.2M
Burning Rock Biotech Limited
BNR · US
Fair value as of: Jun 24, 2026
From 4 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from $40.42 to $40.23 (−0.5%) since Jun 23, 2026. Share price −13.3% over the past month.
Price vs Fair Value (12 months)
12‑month range $2.86 – $38.42 · fair‑value band $30.17 – $50.28 · the $7.56 price screens below the $40.23 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Burning Rock Biotech Limited (BNR) currently trades at $7.56, while our model-based Fair Value estimate is $40.23 — implying the stock looks roughly 432.1% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Burning Rock Biotech Limited generated revenue of $514M at a net margin of -11.5%. Revenue declined 18.9% year over year. It earns a return on equity of -10.9%. The balance sheet holds a net cash position of $438M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for asses…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Burning Rock Biotech Limited reported revenue of $540M in FY2025 versus $508M in FY2021, a compound +1.5%/yr. Reported net income was −$55.3M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $464.01 | $326.81 | -30% |
| Danaher Corporation DHR | $183.63 | $87.65 | -52% |
| WuXi AppTec Co WUXAY | $18.59 | $25.09 | +35% |
| IDEXX Laboratories, Inc IDXX | $562.16 | $190.95 | -66% |
| Lonza Group LZAGY | $61.97 | $14.23 | -77% |
| Agilent Technologies, Inc A | $131.62 | $60.93 | -54% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Burning Rock Biotech Limited (BNR) undervalued?
What is the fair value of BNR?
What is the quality score of BNR?
What is the revenue of Burning Rock Biotech Limited (BNR)?
What is the net profit margin of BNR?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.